Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy

• Status: Not yet recruiting
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The clinical purpose of this study was to investigate whether the adjuvant application of linaclotide in bowel preparation for colonoscopy could improve the quality of bowel preparation or reduce the dosage of laxatives.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Changhai Hospital
• Collaborators: Affiliated Hospital of Inner Mongolia Medical University; Affiliated Hospital of Qingdao University; Affiliated Hospital of Qinghai University; Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Zunyi Medical University; Daping Hospital, Army Military Medical University; Huizhou Municipal Central Hospital; Ningxia Medical University General Hospital; Qilu Hospital of Shandong University; Ruian People's Hospital; Ruijin Hospital; Shanxi Provincial People's Hospital; The 7th Medical Center of the PLA General Hospital; The 900th Hospital of the PLA; The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Xi 'an Jiaotong University; The First Hospital of Jilin University; The First Hospital of Shihezi University; The Second Affiliated Hospital of Dalian Medical University; The Second Hospital of Hebei Medical University; Xiangya Second Hospital, Central South University; Yueqing People's Hospital; Yunnan First People's Hospital; Zhongnan Hospital Affiliated to Wuhan University
• Treatments: Linaclotide

Criteria

Inclusion Criteria:

• 18-75 years old, male or female;

• To undergo diagnostic, screening or monitoring colonoscopy;

• Signed written informed consent;

Exclusion Criteria:

• Severe cardiopulmonary insufficiency, renal failure or a history of stroke or myocardial infarction within six months;

• History of abdominal or pelvic surgery;

• Pregnant and lactating women;

• BMI > 28, BMI < 18.5, inflammatory bowel disease, constipation (defecation less than 3 times in the last week, and laborious defecation, fecal sclerosis, low volume) or intestinal obstruction and other high-risk factors of intestinal preparation;

• Abnormal coagulation function or taking antiplatelet or anticoagulant drugs within 7 days;

• Warning symptoms and signs of colorectal cancer: hematochezia, melena, unexplained anemia, low body weight, abdominal mass, positive digital rectal test; or imaging and laboratory tests highly suspect colorectal cancer;

• Colon polyps have been identified;

• Stow score 7 (watery, no solid mass), diarrhea was considered;

• Participation in other interventional clinical trials within 60 days.